Vestmark Advisory Solutions Inc. Has $1.60 Million Stock Position in Stryker Corporation $SYK

Key Points

• Vestmark Advisory Solutions Inc. increased its holdings in Stryker Corporation by 136.6% in Q1, amounting to 4,304 shares valued at approximately $1.6 million.
• The company reported $3.13 EPS for the last quarter, exceeding analyst expectations, with a revenue increase of 11.1% year-over-year.
• Stryker announced a quarterly dividend of $0.84 per share, set to be paid on October 31st, with a dividend yield of 0.9%.

Vestmark Advisory Solutions Inc. lifted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 136.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,304 shares of the medical technology company's stock after acquiring an additional 2,485 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Stryker were worth $1,602,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of SYK. Elefante Mark B bought a new position in shares of Stryker in the fourth quarter worth $337,000. Mogy Joel R Investment Counsel Inc. increased its position in shares of Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after purchasing an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. increased its position in shares of Stryker by 1.9% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after purchasing an additional 3,341 shares during the period. Harbor Capital Advisors Inc. bought a new position in shares of Stryker in the first quarter worth $1,840,000. Finally, Mar Vista Investment Partners LLC increased its position in shares of Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after purchasing an additional 8,353 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 2.2%

Shares of SYK stock traded up $8.3540 during mid-day trading on Tuesday, reaching $389.9640. 1,691,504 shares of the stock traded hands, compared to its average volume of 1,344,400. The stock's fifty day simple moving average is $386.87 and its two-hundred day simple moving average is $379.45. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $149.09 billion, a price-to-earnings ratio of 51.65, a price-to-earnings-growth ratio of 2.77 and a beta of 0.91. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same period last year, the firm posted $2.81 earnings per share. The business's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SYK. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Roth Mkm raised their price target on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. BTIG Research restated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Finally, Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.